Brad Diephuis Named CEO of Thyme Care as Robin Shah Becomes Executive Chairman
Published by
OncoDaily
on
Summary:
-
Thyme Care named Brad Diephuis, MD, chief executive officer effective September 1, 2026. Diephuis has served as president and chief operating officer since joining in 2022.
-
Co-founder Robin Shah becomes executive chairman, co-founder Bobby Green, MD, continues as president and chief medical officer, and Marcia Macphearson joins as chief operating officer effective immediately.
Thyme Care has announced a series of leadership changes intended to support the continued growth of its oncology care platform while opening new areas of business focused on some of the most persistent challenges across cancer care.
Brad Diephuis, MD, currently Thyme Care’s president and chief operating officer, has been appointed chief executive officer. He will assume the position on September 1, 2026.
Co-founder Robin Shah will transition from chief executive officer to executive chairman, where he will focus on developing new business lines across drug affordability, clinical trial access, and care alignment. Marcia Macphearson has joined the company as chief operating officer, effective immediately, while co-founder Bobby Green, MD, will continue serving as president and chief medical officer.
A New Leadership Structure for Thyme Care’s Next Chapter
The leadership transition comes as Thyme Care seeks to scale its established oncology care model while pursuing opportunities beyond its core operations.
The company’s platform is currently available to 10.5 million people across all 50 US states and manages approximately $6 billion in oncology spending. Thyme Care works with patients, oncology providers, health plans, employers, and risk-bearing organizations to coordinate care across the cancer journey.
Under the new structure, Diephuis will lead the company’s core business and continued expansion, while Shah will concentrate on launching initiatives addressing broader systemic barriers affecting cancer care.
Thyme Care stated that the changes reflect the strength of the business developed during the company’s first six years and its plans to expand into areas where fragmentation continues to create barriers for patients, providers, and payers.
Brad Diephuis to Lead Continued Growth
Diephuis is a primary care physician with experience spanning clinical medicine, healthcare operations, public policy, and value-based care strategy.
He joined Thyme Care in 2022 and has played a central role in developing the company’s operations and payer expansion strategy. Before joining Thyme Care, he served as a senior advisor at the Center for Medicare and Medicaid Innovation, where he contributed to the development of accountable care and total-cost-of-care programs, including ACO REACH.
Diephuis is also a cancer survivor, an experience that has informed his understanding of the challenges patients face while navigating a complex healthcare system.
“For too long, the responsibility for what happens in cancer care has been spread across so many parties that no one is connecting the dots for the person living through it,” Diephuis said.
He noted that Thyme Care was created to place patients at the center of care and bring greater coordination among the organizations involved in their treatment.
“As CEO, I am committed to making sure that every patient, clinician, and health plan we work with experiences a system that finally moves together, where patients feel supported, providers have a trusted partner, and health plans can rely on a model that delivers sustainable value,” he added.